Last reviewed · How we verify
Ciproxin 750 mg
Ciproxin 750 mg is a Small molecule drug developed by Future University in Egypt. It is currently in Phase 1 development. Also known as: Reference product (R).
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ciproxin 750 mg |
|---|---|
| Also known as | Reference product (R) |
| Sponsor | Future University in Egypt |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Somnolence
- Urticaria
- Upperrespiratory tract infection
- Diarrhoea
- Nausea
- Back pain
- Dermatitis contact
- Headache
- Anal fissure
- Chest discomfort
- Decreased appetite
- Dizziness postural
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) (PHASE2, PHASE3)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) (PHASE2, PHASE3)
- Success of Lesion Sterilization and Tissue Repair Therapy (PHASE4)
- Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis (PHASE4)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (PHASE2, PHASE3)
- Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciproxin 750 mg CI brief — competitive landscape report
- Ciproxin 750 mg updates RSS · CI watch RSS
- Future University in Egypt portfolio CI
Frequently asked questions about Ciproxin 750 mg
What is Ciproxin 750 mg?
Who makes Ciproxin 750 mg?
Is Ciproxin 750 mg also known as anything else?
What development phase is Ciproxin 750 mg in?
What are the side effects of Ciproxin 750 mg?
Related
- Manufacturer: Future University in Egypt — full pipeline
- Also known as: Reference product (R)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing